Buchsbaum D.J., Zhou T., Lobuglio A.F. 2006. TRAIL receptor-targeted therapy. Future Oncol. 2 (4), 493–508. https://doi.org/10.2217/14796694.2.4.493

Article  CAS  PubMed  Google Scholar 

Chamuleau M.E., Ossenkoppele G.J., van Rhenen A., van Dreunen L., Jirka S.M., Zevenbergen A. 2011. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res. 35 (6), 741–749. https://doi.org/10.1016/j.leukres.2010.12.032

Article  CAS  PubMed  Google Scholar 

Kaufmann S.H., Steensma D.P. 2005. On the TRAIL of a new therapy for leukemia. Leukemia. 19 (12), 2195–2202. https://doi.org/10.1038/sj.leu.2403946

Article  CAS  PubMed  Google Scholar 

Thapa B., Kc R., Uludag H. 2020. TRAIL therapy and prospective developments for cancer treatment. J. Control. Release. 326, 335–349. https://doi.org/10.1016/j.jconrel.2020.07.013

Article  CAS  PubMed  Google Scholar 

Snajdauf M., Havlova K., Vachtenheim J.Jr., Ozaniak A., Lischke R., Bartunkova J., Smrz D., Strizova Z. 2021. The TRAIL in the treatment of human cancer: An update on clinical trials. Front. Mol. Biosci. 8, 628332. https://doi.org/10.3389/fmolb.2021.628332

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fadeev R., Chekanov A., Solovieva M., Bezborodova O., Nemtsova E., Dolgikh N., Fadeeva I., Senotov A., Kobyakova M., Evstratova Y., Yakubovskaya R., Akatov V. 2019. Improved anticancer effect of recombinant protein izTRAIL combined with sorafenib and peptide iRGD. Int. J. Mol. Sci. 20 (3), 525. https://doi.org/10.3390/ijms20030525

Article  CAS  PubMed  PubMed Central  Google Scholar 

Testa U. 2010. TRAIL/TRAIL-R in hematologic malignancies. J. Cell Biochem. 110 (1), 21–34. https://doi.org/10.1002/jcb.22549

Article  CAS  PubMed  Google Scholar 

Riccioni R., Pasquini L., Mariani G., Saulle E., Rossini A., Diverio D., Pelosi E., Vitale A., Chierichini A., Cedrone M., Foà R., Lo Coco F., Peschle C., Testa U. 2005. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica. 90 (5), 612–624.

CAS  PubMed  Google Scholar 

Austin R., Smyth M.J., Lane S.W. 2016. Harnessing the immune system in acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 103, 62–77. https://doi.org/10.1016/j.critrevonc.2016.04.020

Article  PubMed  Google Scholar 

Sag D., Ayyildiz Z.O., Gunalp S., Wingender G. 2019. The role of TRAIL/DRs in the modulation of immune cells and responses. Cancers (Basel). 11 (10), 1469. https://doi.org/10.3390/cancers11101469

Article  CAS  PubMed  Google Scholar 

Cheng J., Hylander B.L., Baer M.R., Chen X., Repasky E.A. 2006. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol. Cancer Ther. 5 (7), 1844–1853. https://doi.org/10.1158/1535-7163.MCT-06-0050

Article  CAS  PubMed  Google Scholar 

Kobyakova M.I., Evstratova Y.V., Senotov A.S., Lomovsky A.I., Minaichev V.V., Zvyagina A.I., Solovieva M.E., Fadeeva I.S., Akatov V.S., Fadeev R.S. 2021. Appearance of signs of differentiation and pro-inflammatory phenotype in acute myeloid leukemia cells THP-1 at their Increased TRAIL resistance in cell aggregates in vitro. Biochem. (Moscow), Suppl. Series A: Membr. Cell Biol. 15 (1), 97–105. https://doi.org/10.1134/S1990747821010050

Article  CAS  Google Scholar 

Lomovskaya Y.V., Kobyakova M.I., Senotov A.S., L-omovsky A.I., Minaychev V.V., Fadeeva I.S., Shtatnova D.Y., Krasnov K.S., Zvyagina A.I., Akatov V.S., Fadeev R.S. 2022. Macrophage-like THP-1 cells derived from high-density cell culture are resistant to TRAIL-induced cell death via down-regulation of death-receptors DR4 and DR5. Biomolecules. 12 (2), 150. https://doi.org/10.3390/biom12020150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evstratova Y.V., Kobyakova M.I., Novikova V.V., Senotov A.S., Akatov V.S., Fadeev R.S. 2019. Monocyte-macrophage differentiation suppresses the expression of proapoptotic receptors to Apo2L/TRAIL and increases resistance to TRAIL-induced apoptosis. Biophysics. 64, 729–731. https://doi.org/10.1134/S0006350919050038

Article  CAS  Google Scholar 

Shiiki K., Yoshikawa H., Kinoshita H., Takeda M., Ueno A., Nakajima Y., Tasaka K. 2000. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ. 7 (10), 939–946. https://doi.org/10.1038/sj.cdd.4400727

Article  CAS  PubMed  Google Scholar 

Bamezai S., Buske C. 2019. Cutting Off Leukemogenesis: Hydra-like plasticity of mature leukemic cells. Cell Stem Cell. 25 (2), 167–168. https://doi.org/10.1016/j.stem.2019.07.005

Article  CAS  PubMed  Google Scholar 

McKenzie M.D., Ghisi M., Oxley E.P., Ngo S., Cimmino L., Esnault C., Liu R., Salmon M.J., Bell C.C., Ahmed N., Erlichster M., Witkowski T.M., Liu J.G., Chopin M., Dakic A., Simankowicz E., Pomilio G., Vu T., Krsmanovic P., Su S., Tian L., Baldwin M.T., Zalcenstein A.D., DiRago L., Wang S., Metcalf D., Johnstone W.R., Croker A.B., Lancaster I.G., M-urphy J.A., Naik H.S., Nutt L.S., Pospisil V., Schroeder T., Wall M., Dawson A.M., Wei H.A., de Thé H., Ritchie E.M., Zuber J., Dickins A.R. 2019. Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. Cell Stem Cell. 25 (2), 258–272. https://doi.org/10.1016/j.stem.2019.07.001

Article  CAS  PubMed  Google Scholar 

Ngo S., Oxley E.P., Ghisi M., Garwood M.M., McKenz-ie M.D., Mitchell H.L., Kanellakis P., Susanto O., Hickey M.J., Perkins A.C., Kile B.T., Dickins R.A. 2021. Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nat. Commun. 12 (1), 6546. https://doi.org/10.1038/s41467-021-26849-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyd A.L., Aslostovar L., Reid J., Ye W., Tanasijevic B., Porras D.P., Shapovalova Z., Almakadi M., Foley R., Leber B., Xenocostas A., Bhatia M. 2019. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell. 34 (3), 483–498. https://doi.org/10.1016/j.ccell.2018.08.007

Article  CAS  Google Scholar 

Pei S., Pollyea D.A., Gustafson A., Stevens B.M., Minhajuddin M., Fu R., Riemondy A.K., Gillen E.A., Sheridan M.R., Kim J., Costello C.J., Amaya L.M., Inguva A., Winters A., Ye H., Krug A., Jones L.C., Adane B., Khan N., Ponder J., Schowinsky J., Abbott D., Hammes A., Myers R.J., Ashton M.J., Nemkov T., D’Alessandro A., Gutman A.J., Ramsey E.H., Savona R.M., Smith A.C., Jordan T.C. 2020. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10 (4), 536–551. https://doi.org/10.1158/2159-8290.CD-19-0710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuusanmaki H., Leppa A.M., Polonen P., Kontro M., Dufva O., Deb D., Yadav B., Brück O., Kumar A., Everaus H., Gjertsen T.B., Heinäniemi M., Porkka K., Mustjoki S., Heckman A.C. 2020. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 105 (3), 708–720. https://doi.org/10.3324/haematol.2018.214882

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drach J., Lopez-Berestein G., McQueen T., Andreeff M., Mehta K. 1993. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. 53 (9), 2100–2104.

CAS  PubMed  Google Scholar 

Daigneault M., Preston J.A., Marriott H.M., Whyte M.K., Dockrell D.H. 2010. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One. 5 (1), e8668. https://doi.org/10.1371/journal.pone.0008668

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forrester M.A., Wassall H.J., Hall L.S., Cao H., Wilson H.M., Barker R.N., Vickers A.M. 2018. Similarities and differences in surface receptor expression by THP-1 monocytes and differentiated macrophages polarized using seven different conditioning regimens. Cell Immunol. 332, 58–76. https://doi.org/10.1016/j.cellimm.2018.07.008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newburger P.E., Chovaniec M.E., Greenberger J.S., Cohen H.J. 1979. Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J. Cell Biol. 82 (2), 315–322. https://doi.org/10.1083/jcb.82.2.315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tasseff R., Jensen H.A., Congleton J., Dai D., Rogers K.V., Sagar A., Bunaciu R.P., Yen A., Varner J.D. 2017. An effective model of the retinoic acid induced HL-60 differentiation program. Sci. Rep. 7 (1), 14327. https://doi.org/10.1038/s41598-017-14523-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baxter S.S., Carlson L.A., Mayer A.M., Hall M.L., Fay M.J. 2009. Granulocytic differentiation of HL-60 promyelocytic leukemia cells is associated with increased expression of Cul5. In Vitro Cell Dev. Biol. Anim. 45 (5–6), 264–274. https://doi.org/10.1007/s11626-008-9163-4

Article  CAS  PubMed  Google Scholar 

Huang R., Zhao L., Chen H., Yin R.H., Li C.Y., Zhan Y.Q., Zhang J.H., Ge C., Yu M., Yang X.M. 2014. Megakaryocytic differentiation of K562 cells induced by PMA reduced the activity of respiratory chain complex IV. PLoS One. 9 (5), e96246. https://doi.org/10.1371/journal.pone.0096246

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim K.W., Kim S.H., Lee E.Y., Kim N.D., Kang H.S., Kim H.D., Chung B.S., Kang C.D. 2001. Extracellular signal-regulated kinase/90-KDA ribosomal S6 kinase/nuclear factor-kappa B pathway mediates phorbol 12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells. J. Biol. Chem. 276 (16), 13 186–13 191. https://doi.org/10.1074/jbc.M008092200

Article  Google Scholar 

Nurhayati R.W., Ojima Y., Nomura N., Taya M. 2014. Promoted megakaryocytic differentiation of K562 cells through oxidative stress caused by near ultraviolet irradiation. Cell Mol. Biol. Lett. 19 (4), 590–600. https://doi.org/10.2478/s11658-014-0215-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrera R., Hubbell S., Decker S., Petruzzelli L. 1998. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: Modulation of megakaryocytic differentiation of K562 cells. Exp. Cell Res. 238 (2), 407–414. https://doi.org/10.1006/excr.1997.3847